Economic Evaluations of Medical Cost Differences: Use of Targeted-Specific Oral Anticoagulants vs. Warfarin among Patients with Nonvalvular Atrial Fibrillation and Venous Thromboembolism in the U.S.

Alpesh Amin^1*, Melissa Lingohr-Smith², Amanda Bruno³, Jeffrey Trocio⁴ and Jay Lin²

¹University of California, Irvine, CA, USA

²Novosys Health, Green Brook, NJ, USA

³Bristol-Myers Squibb, Plainsboro, NJ, USA

⁴Pfizer, Inc., New York, NY, USA

^*Corresponding Author: Alpesh Amin, MD, Chair, Executive Director, Hospitalist Program, Department of Medicine, School of Medicine University of California, Irvine, UCIMC; 101 The City Drive South Building 58, Room 110, ZC-4076H, Mail Code: 4076, Irvine, CA 92868, USA, Tel: 714 456-3785 Email: